Invitation to submit Phase II contract proposal, Qrono Inc., 75N93023C00034
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $3,000,000 to $7,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
-
- Wolfgang Leitner wleitner@niaid.nih.gov
- Callie Prassinos callie.prassinos@nih.gov (240) 669-5155
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health is inviting Qrono Inc. to submit a Phase II contract proposal under contract 75N93023C00034, with an estimated award date of 2027-06-01. The requirement, a new forecast following Qrono's Phase I SBIR work on screening methods for tolerogenic adjuvants, will use those methods to discover and down-select new adjuvants for preventing and/or treating allergy and autoimmunity. The estimated solicitation release date is 2026-10-01, and the requirement is set aside for total small business under NAICS 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology).
The estimated award value range is $3.0 million to $7.0 million. Points of contact are Wolfgang Leitner, Chief, Innate Immunity Section, National Institutes of Health (wleitner@niaid.nih.gov), and Callie Prassinos, Contracting Officer, NIH (callie.prassinos@nih.gov, +1 240-669-5155).
Forecast text
This is a request for Qrono Inc. to be invited to submit a Phase II contract proposal. This contractor previously provided benefit to the government during a Phase I SBIR contract by developing new screening methods for discovering tolerogenic adjuvants. This invitation for a Phase II contract proposal will further benefit the government by allowing a new proposal that utilizes these new screening methods to discover and down-select new adjuvants that can be used to prevent and/or treat allergy and autoimmunity.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast